TipRanks
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
US Market
BLTE
Belite Bio, Inc. ADR
RESEARCH TOOLSreports
Want to see BLTE full AI Analyst Report?

Belite Bio, Inc. ADR (BLTE) Stock News & Sentiment

72 Followers
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease
Premium
Company Announcements
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease
25d ago
6K
BLTE
Belite Bio Earnings Call Highlights Tinlarebant Momentum
Premium
Company Announcements
Belite Bio Earnings Call Highlights Tinlarebant Momentum
1M ago
BLTE
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out
Premium
Company Announcements
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out
2M ago
6K
BLTE
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating
Premium
Ratings
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating
2M ago
BLTE
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
Premium
Company Announcements
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
2M ago
6K
BLTE
BLTE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
BLTE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
BLTE
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target
Premium
Ratings
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target
5M ago
BLTE
More BLTE News >

BLTE News on the Web

Belite Bio management to meet with Piper Sandler
TipRanks News
Bullish
Belite Bio, Inc at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Belite Bio (BLTE) CEO Yu-hsin Lin Sells 100,435 Shares, Insider Ownership Drops to 70,134 Shares
GuruFocus News
Bearish
Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1
TipRanks News
Bullish
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease
TipRanks News
Neutral
Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
TipRanks News
Bullish
Belite Bio Pops As Wall Street Backs Stargardt Bet
TipRanks News
Bullish
Canaccord starts Belite Bio at Buy on additional post-IPO upside
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
BLTE
Sector Average
Media Buzz
This Week1 articles
Weekly Average5 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BLTE’s Media Buzz Sentiment?
1 articles about BLTE were published this week. In an average week, 5 articles are published.
    What is BLTE’s weekly average amount of articles?
    In an average week, 5 articles about BLTE are published.
      What is BLTE’s News Sentiment?
      100% of articles about BLTE were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        SYRESpyre Therapeutics
        BAYRYBayer
        QTTBQ32 Bio
        CICigna
        ZYMEZymeworks
        Showing the stocks with the most bullish news sentiment over the past week